OncoPharm 2024 New Drug Review
7 snips
Dec 19, 2024 Reflecting on the innovative cancer therapies approved in 2024, the discussion likens these breakthroughs to holiday gifts. Each drug is categorized as either 'keep', 're-gift', or 'return', offering a fun framework to explore their potential impact. Discover the latest advancements in oncology and what they mean for patients and the pharmaceutical landscape. Just as the review wraps up, two new approvals are announced, adding even more excitement to this year's innovations!
AI Snips
Chapters
Transcript
Episode notes
5-FU Label Update Analogy
- John Bazar uses a Taylor Swift sweatshirt analogy to describe the updated 5-FU label.
- It acknowledges DPYD deficiency risks, but doesn't mandate testing, like he'd hoped.
Tarlatimab's Impact
- Tarlatimab's approval, the first bispecific for solid tumors, was unexpected but welcomed.
- Bazar likens the excitement to receiving an 8-bit Nintendo as a child.
Complex Drug Use
- Some drugs are too complex for general use, like giving grandparents new tech they can't use.
- Bazar suggests "re-gifting" such drugs to specialists.